Clinical trial
A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.
NCT01771458 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.
- Lead sponsor
- Institut Curie
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2012
- Completion date
- December 31, 2016
- Enrollment
- 742 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
reccurent/metastatic solid tumor disease